Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Pathologic Complete Response × Folfox protocol × 90 days × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 13 Colonic Neoplasms 4 Stomach Neoplasms 3 Rectal Neoplasms 3 Neoplasm Metastasis 3 Carcinoma, Non-Small-Cell Lung 3 Cholangiocarcinoma 2 Biliary Tract Neoplasms 2 Pathologic Complete Response 1 Lung Neoplasms 1 Gastrointestinal Neoplasms 1 Gastroesophageal Adenocarcinoma 1 Gallbladder Neoplasms 1 Esophageal Neoplasms 1 Colorectal Cancer Metastatic 1 Cirrhosis, Familial, with Pulmonary Hypertension 1 Breast Neoplasms 1 Adenocarcinoma Of Esophagus 1

Interventions

pembrolizumab 2 durvalumab 2 Standard of Care 2 Paclitaxel 2 Oxaliplatin 2 Irinotecan 2 Chemoradiotherapy 2 Carboplatin 2 Capecitabine 2 zanidatamab 1 veliparib 1 tucatinib 1 trilaciclib 1 trebananib 1 trastuzumab duocarmazine 1 tislelizumab 1 tegafur-gimeracil-oteracil 1 talazoparib 1 sarilumab 1 relugolix 1 regorafenib 1 pexidartinib 1 pertuzumab 1 patritumab 1 olaparib 1 niraparib 1 neratinib 1 ganitumab 1 enzalutamide 1 dostarlimab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07472868 2026-03-16

MEND-IT II

Catharina Ziekenhuis Eindhoven

Phase 3 Not yet recruiting

Pathologic Complete Response

Data powered by HemOnc (CC BY 4.0) Colophon ⚡